Juan Vicente-Valor

Mr. Juan Vicente-Valor

Biochemistry and Molecular Biology Department, Complutense University of Madrid, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JVJuan Vicente-Valor
Juan Vicente-Valor
XGXandra García-González
Xandra García-González
SISara Ibáñez-García
Sara Ibáñez-García
MDMaría Esther Durán-García
María Esther Durán-García
ALAna de Lorenzo-Pinto
Ana de Lorenzo-Pinto
MSMaría Sanjurjo-Sáez
María Sanjurjo-Sáez
Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have emerged as a therapeutic option for patients with hypercholesterolemia who do not attain low-density lipoprotein cholesterol (LDL-C) goals and/or are intolerant to other lipid-lowering drugs. Our aim was to analyze the effectiveness and safety of PCSK9i in routine clinical practice and factors related to poor outcomes. We conducted an ambispective study in 115 patients who recieved alirocumab or evolocumab, in a tertiary level hospital. From February 2017 to April 2020, patients were recruited and followed up for a median of 20.4 months. The main outcomes were relative reduction in LDL-C, percentage of patients achieving the therapeutic goals established by 2016 ESC/EAS guidelines, incidence of major cardiovascular events (MACEs) and drug-related adverse events (ADRs). The median LDL-C achieved was 57.0 mg/dL (relative reduction of 59.9% from baseline, p< 0.001). After adjusting for confounders, smaller LDL-C reductions were related to female sex, absence of concomitant lipid-lowering therapy and treatment with alirocumab. Overall, 84.6% of the patients achieved the therapeutic goals. During follow-up, 7 MACEs were detected. ADRs, generally considered mild, affected 38.1% of the participants (mainly mialgias and arthralgias) and triggered discontinuations in 8.7% of cases. PCSK9i are effective and safe, although certain factors may influence their effectiveness. Interestingly, our results suggest that alirocumab and evolocumab may not be therapeutic equivalents, as initially suggested.

21 March 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
STSofia Elena Tesolato
Sofia Elena Tesolato
JVJuan Vicente-Valor
Juan Vicente-Valor
MPMateo Paz-Cabezas
Mateo Paz-Cabezas
DGDulcenombre Gomez-Garre
Dulcenombre Gomez-Garre
SGSilvia Sánchez González
Silvia Sánchez González
PIPilar Iniesta
Pilar Iniesta
The application of bacterial metagenomic analysis as a biomarker for cancer detection is emerging. Our aim was to discover gut microbiota signatures with potential utility in the diagnosis of colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). A prospective study was performed on a total of 77 fecal samples from CRC and NSCLC patients and controls. DNA from stool was analyzed for bacterial genomic sequencing using the Ion Torrent™ technology. Bioinformatic analysis was performed using the QIIME2 pipeline. We applied logistic regression to adjust for differences attributable to sex, age, and body mass index, and the diagnostic accuracy of our gut signatures was compared with other previously published results. The feces of patients affected by different tumor types, such as CRC and NSCLC, showed a differential intestinal microbiota profile. After adjusting for confounders, Parvimonas (OR = 53.3), Gemella (OR = 6.01), Eisenbergiella (OR = 5.35), Peptostreptococcus (OR = 9.42), Lactobacillus (OR = 6.72), Salmonella (OR = 5.44), and Fusobacterium (OR = 78.9) remained significantly associated with the risk of CRC. Two genera from the Ruminococcaceae family, DTU089 (OR = 20.1) and an uncharacterized genus (OR = 160.1), were associated with the risk of NSCLC. Our two panels had better diagnostic capacity for CRC (AUC = 0.840) and NSLC (AUC = 0.747) compared to the application of two other published panels to our population. Thus, we propose a gut bacteria panel for each cancer type and show its potential application in cancer diagnosis.

8 December 2022 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PRPaula Ruiz-Briones
Paula Ruiz-Briones
VEVicente Escudero-Vilaplana
Vicente Escudero-Vilaplana
RCRoberto Collado-Borrell
Roberto Collado-Borrell
JVJuan Vicente-Valor
Juan Vicente-Valor
RARosa Alvarez
Rosa Alvarez
MSMaria Sanjurjo
Maria Sanjurjo
Introduction: Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) indicated for the treatment of epidermal growth factor receptor mutated non-small cell lung cancer (NSCLC). It has demonstrated better results concerning effectiveness than other TKIs for the same indication. However, despite a good safety profile, it could produce some cardiotoxicity that does not occur with other drugs of the same group. Case report: We report the evolution and management of a female patient diagnosed with NSCLC who developed a grade 3 cardiotoxicity due to treatment with osimertinib. This patient suffered from a left bundle branch block, dyslipidemia, and hypertension as cardiovascular risk factors. After a long period of treatment with osimertinib, she developed a severe heart failure (HF) with an important decrease in left ventricular ejection fraction (LVEF), which triggered an admission to the oncology unit for eight days. Management and outcomes: Treatment with osimertinib was first suspended and then resumed after stabilization of the HF. She also developed atrial fibrillation during admission and has required narrow cardiac monitoring and management since the debut of the HF. After evaluating the benefit-risk balance, osimertinib was reintroduced and the patient continues in treatment at the moment, although the baseline LVEF is not recovered. Discussion: There is scarce evidence in the literature concerning HF and important LVEF decrease due to osimertinib. However, its severity and repercussion for the patient justify the thorough screening of cardiovascular risk factors before starting the therapy.

1 September 2023 in Pharmacological Reports
Verified
Journal Article
Closed access
PDF file
JVJuan Vicente-Valor
Juan Vicente-Valor
CRCarmen Rodríguez-González
Carmen Rodríguez-González
MFMaría Ferris-Villanueva
María Ferris-Villanueva
ECEsther Chamorro-De-Vega
Esther Chamorro-De-Vega
RRRosa Romero-Jiménez
Rosa Romero-Jiménez
MSMaría Sanjurjo-Sáez
María Sanjurjo-Sáez

28 March 2026 in Lung Cancer
Verified
Journal Article
Open access
JVJuan Vicente-Valor
Juan Vicente-Valor
CACarlos Aguado
Carlos Aguado
MMMaría Mateos
María Mateos
STSofia Elena Tesolato
Sofia Elena Tesolato
MAMónica Antoñanzas
Mónica Antoñanzas
JGJosé-Luis González-Larriba
José-Luis González-Larriba
Intratumoral microbiota is being investigated as a potential biomarker in cancer. In this study, we investigated tissue microbiota in advanced non-small cell lung cancer (NSCLC) to evaluate response to immune checkpoint inhibitors (ICIs). We performed a retrospective study in 41 tumor tissues from patients with advanced NSCLC treated with ICI +/- chemotherapy. Microbial profiling was analyzed through 16S rRNA amplicon sequencing using Ion Torrent technology. Bioinformatic analysis was performed with the QIIME2 pipeline. Cox and logistic regression identified two bacterial consortia with prognostic relevance in terms of overall survival (OS), progression-free survival (PFS) and treatment response: the KBUBe score, which included four genera (Klebsiella, Brevundimonas, Undibacterium and Beijerinckiaceae), and the OSAA score, which comprised Olsenella, Salinarimonas, Actinobacillus and Lachnospiraceae genus A2. KBUBe and OSAA scores were significant predictors of OS (hazard ratio [HR] = 0.501, p = 0.009 and HR = 0.491, p < 0.001, respectively) and PFS (HR = 0.579, p = 0.040 and HR = 0.133, p < 0.001, respectively), outperforming PD-L1 expression, ECOG performance status or neutrophil-to-lymphocyte ratio. All patients with the highest KBUBe score were responders, compared with 50% in the lowest-score group (p = 0.035). Similarly, 83.8% of patients with the highest OSAA score were responders, whereas no responders were observed in the lowest-score group (p = 0.001). These findings were confirmed by internal validation and were not confounded by tobacco smoking status, type of therapy and histology. Intratumoral microbial communities are associated with survival and treatment response in ICI-treated NSCLC. The KBUBe and OSAA scores represent novel, independent prognostic biomarkers, warranting validation in larger cohorts.

17 January 2022 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
JVJuan Vicente-Valor
Juan Vicente-Valor
VEVicente Escudero-Vilaplana
Vicente Escudero-Vilaplana
RCRoberto Collado-Borrell
Roberto Collado-Borrell
CLCristina López-López
Cristina López-López
CVCristina Villanueva-Bueno
Cristina Villanueva-Bueno
MSMaría Sanjurjo
María Sanjurjo
Introduction: Spironolactone when combined with abiraterone in metastatic castration-resistant prostate cancer (mCRPC) may theoretically exert androgenic properties, thereby compromising the therapeutic effectiveness of abiraterone. Case report: Two patients with a medical history of cardiovascular disease and mCRPC combined spironolactone within the course of abiraterone regimen. The abiraterone-spironolactone interaction was identified using the Lexicomp® interaction tool (classified as risk C). Management & outcome: Spironolactone treatment was maintained as it was considered beneficial due to the cardiac condition. The prostate-specific antigen (PSA) levels started to rise when these two drugs were used together. Eventually, tumour progression was observed. Discussion: There is increasing evidence that spironolactone behaves as a selective androgen receptor modulator. Strategies to overcome abiraterone-spironolactone interaction could involve the use of eplerenone, although this drug is also controversial. The best strategy should imply a multidisciplinary evaluation by cardiologists and oncologists.